Abstract
Introduction There has been great interest in the prodromal phase of Parkinson’s disease (PD), especially in subjects who are asymptomatic carriers of genetic mutations leading to PD because of the high risk to convert to PD. The objective of the present study was to assess non motor characteristics of asymptomatic p.A53T mutation carriers (A53T-AC) compared with healthy controls (HC).
Methods We compared 12 A53T-AC with 36 matched HC enrolled into in the Parkinson’s Progression Markers Initiative (PPMI) study. Baseline data extracted from the PPMI database, contained demographics and non-motor symptoms (e.g. the Montreal Cognitive Assessment (MOCA) for cognition, the University of Pennsylvania Smell Identification Test (UPSIT) for olfaction, MDS-UPDRS I etc.)
Results The mean UPSIT score was lower in A53T-AC vs HC (p =0.000). MoCA test showed a trend towards lower scores in A53T AC. We found a significant positive correlation between UPSIT score and MOCA in A53T-AC (rs = 0,68, p=0,021) but not in HC. Total scores for MDS-UPDRS I did not differ between the groups but the subscore of anxiety was more prevalent in A53T-AC.
Conclusion The more affected olfaction in A53T-AC may indicate that olfactory function is affected quite early in A53T carriers. The strong positive correlation between UPSIT and MOCA in the A53T-AC group may indicate that cognitive dysfunction and olfactory impairment progress alongside, prior to nigrostriatal degeneration. Anxiety was also more prevalent in A53T-AC and may represent an additional prodromal feature in this group of subjects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by funding from the Parkinson's Progression Markers Initiative (PPMI) study. PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid, Biogen, Bristol‐Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeek, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, Teva, UCB, and Golub Capital. Moreover, this work was supported by grants from the MULTISYN European Program (FP7‐HEALTH.2013.1.2‐1, number 602646). MULTISYN has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration. The funding sources had no involvement in the design, interpretation or writing of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in the preparation of this study were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (http://www.ppmiinfo.org/data).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Study Funding: This study was supported by funding from the Parkinson’s Progression Markers Initiative (PPMI) study. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbvie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeek, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, Teva, UCB, and Golub Capital. Moreover, this work was supported by grants from the MULTISYN European Program (FP7-HEALTH.2013.1.2-1, number 602646). MULTISYN has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration. The funding sources had no involvement in the design, interpretation or writing of this manuscript.
Financial Disclosure/Conflict of Interest: AM.S. received funding from the Michael J. Fox Foundation for her participation in Parkinson’s Progression Markers Initiative (PPMI). C.K. received funding from the Michael J Fox Foundation for his participation in PPMI. I.B. received funding from the Michael J Fox Foundation for his participation in PPMI. M.S. serves on the editorial boards of Movement Disorders Journal and Frontiers in Movement Disorders and receives research support from the Michael J. Fox Foundation (PPMI). L.S. has received the following grants: MULTISYN European Program (EU, FP7-HEALTH.2013.1.2-1, number 602646), PPMI (supported by the Michael J. Fox Foundation), IMPRIND-IMI2 Number 116060 (EU, H2020), “PBMC and urine collection in LRRK2 and idiopathic PD” Grant by the Michael J. Fox Foundation (collaborator). E.E., D.P., A.B., M.P., E.S., N.P.,R.A., I.P., S.G.P., and P.B., report no disclosures relevant to the manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
